Cancer is one of life’s deadly illnesses especially when being compared to other illnesses in society. This disease has touched of us directly or indirectly in some form or another. Cancer Research has been going on for many years while mostly having little success in wiping the disease out for good. Luckily in the 21st Century cancer research has stepped up it’s game and is supplying the world with much better treatments. One of these special treatments come in the form of Antibody Based Therapies. These therapies stand out when being compared to treatments of the past such as Chemotherapy. Antibody Drug Conjugates are the weapon of choice as they’ll directly deliver cell killing agents straight into cancerous cells. This design and action of the medications actually spare other good cells within the body which decreases any nasty side effects.
Have you ever heard of Seattle Genetics? How about Clay Siegall? Well if you haven’t, Dr. Clay Siegall is the president and (CEO) of Seattle Genetics, which is a Biotech Company that deliver and commercialize breakthrough therapies. Seattle Genetics is the premier organization in this specific industry and it’s flagship drug (ADCETRIS) is the weapon of choice. Dr. Clay Siegall has been in this business for decades and has worked with many of the top cancer research organizations such as Bristol Myers Squibb, The National Institute of Health, as well as The National Cancer Institute. His strong passion and persistence can’t be denied and in 2015, Forbes ranked Seattle Genetics as one of the nation’s fastest growing companies. With such success come significant growth and this company is no exception. As of today this Bothell, Washington based company has well over 800 employees and staff members.
Dr. Clay Siegall has his foot on the gas when it comes to eradicating cancer itself. He implements the principles of drug development, scientific innovation, and rigorous research which has made this company into such a huge success. The future is looking bright in the fight against cancer and Dr. Clay Siegall is steering the ship to success.